目的：探讨早产儿视网膜病变(ROP)抗VEGF治疗后复发的危险因素。

方法：回顾性分析2016-06/2019-10在我院行抗VEGF治疗的ROP患儿56例的临床资料，根据首次抗VEGF治疗后ROP复发情况分为复发组(8例)和非复发组(48 例)。比较两组患儿出生体质量、孕周、血小板体积及是否患有贫血、凝血障碍、败血症、支气管肺发育不良、新生儿呼吸窘迫综合征、窒息、肺炎、颅内出血、卵圆孔未闭、动脉导管未闭等情况，分析抗VEGF治疗后ROP复发的危险因素。

结果：两组患儿出生体质量和出生后颅内出血发生情况有明显差异，Logistic回归分析结果显示，出生低体质量(OR=9.800，P=0.039)和颅内出血(OR=17.571，P=0.002)均是抗VEGF治疗后ROP复发的危险因素。

结论：出生低体质量(<1 000g)和患有颅内出血是抗VEGF治疗后ROP复发的危险因素。

METHODS: A retrospective study about all the infants diagnosed with ROP and treated with anti-VEGF from June 2016 to October 2019 in our hospital. They were divided into recrudescence group(8 cases)and non- recrudescence group(48 cases). The relationship between various clinical risk factors and the recrudescence of ROP after anti-VEGF treatment were considered. Those risk factors included birth weight, gestational age, thrombocytosis, anemia, coagulation disorder, sepsis, bronchopulmonary dysplasia, neonatal respiratory distress syndrome, asphyxia, pneumonia, intracranial hemorrhage, patent foramen ovale, and patency ductus arteriosus.

RESULTS: According to single-factor analysis, birth weight and intracranial hemorrhage showed statistically significant differences between recrudescence group and non-recrudescence group. Logistic regression analysis showed low birth weight(OR=9.800, P=0.039)and intracranial hemorrhage(OR=17.571, P=0.002)had relationship with recrudescence of ROP after anti-VEGF.

CONCLUSION: Low birth weight(<1 000g)and intracranial hemorrhage are the risk factors about recrudescence of ROP after anti-VEGF.